Material Agreements

COLLEGIUM PHARMACEUTICAL, INC entered into Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. (effective 2024-04-26).

“On April 26, 2024, Collegium Pharmaceutical, Inc. (the “Company”) entered into an Authorized Generic Agreement (the “AG Agreement”) with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which the Company granted to Hikma certain rights relating to an authorized generic version of the Company’s Nucynta IR product (the “Nucynta IR Authorized Generic”) and the Company’s Nucynta ER product (the “Nucynta ER Authorized Generic” and, collectively, the “Nucynta AG Products”) in the United States.”

DNA X, Inc. entered into Lock-Up Agreement with the Purchaser (effective 2024-04-29).

“In addition, on April 29, 2024, in connection with the entry into the Subscription Agreement, the Company and the Purchaser entered into a lock-up agreement (the “Lock-Up Agreement”).”

DNA X, Inc. entered into Registration Rights Agreement with the Purchaser (effective 2024-04-29).

“On April 29, 2024, in connection with the entry into the Subscription Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser.”

DNA X, Inc. entered into Subscription Agreement with an individual investor (the Purchaser) valued at $3,850,000 (effective 2024-04-29).

“On April 29, 2024, Sonim Technologies, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with an individual investor identified in the Subscription Agreement (“Purchaser”), providing for the private placement of (i) 3,500,000 shares of the Company’s common stock, par value $0.001, (“Common Stock”) and (ii) warrants to purchase up to 3,500,000 shares of Common Stock (the “Warrants”) for an aggregate purchase price of $3,850,000 (the “Purchase Price”).”

PHIBRO ANIMAL HEALTH CORP entered into Debt Commitment Letter with Coöperatieve Rabobank U.A., New York Branch, Compeer Financial, PCA, Citibank, N.A. valued at $325 million senior secured incremental first lien term loan facility (effective 2024-04-28).

“Phibro entered into a debt commitment letter (the “Commitment Letter”), dated as of April 28, 2024, with Coöperatieve Rabobank U.A., New York Branch (“Rabobank”), Compeer Financial, PCA (“Compeer”) and Citibank, N.A. (“Citibank” and, collectively with Rabobank and Compeer, the “Commitment Parties”) pursuant to which the Commitment Parties have committed to provide a senior secured incremental first lien term loan facility in an aggregate principal amount of $325 million (the “Incremental Term Facility”).”

PHIBRO ANIMAL HEALTH CORP entered into Purchase and Sale Agreement with Zoetis Inc. valued at $350 million (effective 2024-04-28).

“On April 28, 2024, Phibro Animal Health Corporation, a Delaware corporation (“Phibro Animal Health”), and Phibro Animal Health S.A., a Belgium corporation and wholly-owned subsidiary of Phibro Animal Health (together with Phibro Animal Health, “Phibro”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Zoetis Inc., a Delaware corporation (“Zoetis”) to acquire Zoetis’ medicated feed additive (MFA) product portfolio, certain water soluble products and related assets (the “Purchased Business”).”

UMB FINANCIAL CORP entered into Agreement and Plan of Merger with Heartland Financial USA, Inc. and Blue Sky Merger Sub Inc. (effective 2024-04-28).

“On April 28, 2024 (the “Signing Date”), UMB Financial Corporation, a Missouri corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Heartland Financial USA, Inc., a Delaware corporation (“HTLF”) and Blue Sky Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Blue Sky Merger Sub”).”

AZZ INC entered into Underwriting Agreement with Evercore Group L.L.C. and Jefferies LLC as representatives of the several underwriters valued at $67.20 per share (effective 2024-04-25).

“On April 25, 2024, AZZ Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Evercore Group L.L.C. (“Evercore”) and Jefferies LLC (“Jefferies”) as representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters an aggregate of 4,000,000 shares of common stock, par value $1.00 per share, of the Company (“Common Stock”), in an underwritten public offering at a purchase price of $67.20 per share (the “Purchase Price”), which reflects a price to the public of $70.00 per share less $2.80 per share (the “Offering”).”

Aptose Biosciences Inc. amended Amended and Restated Warrant to Purchase Common Shares with Hanmi Pharmaceutical Co., Ltd. valued at 2,339,181 warrants at $1.71 per share (effective 2024-04-24).

“On April 24, 2024, Aptose Biosciences Inc. (the “ Company ”) entered into an Amended and Restated Warrant to Purchase Common Shares (the “ Amended Warrant Agreement ”) with Hanmi Pharmaceutical Co., Ltd. (“ Hanmi ”) in order to comply with Listing Rule 5635 of The Nasdaq Stock Market LLC (“ Nasdaq ”).”

DELCATH SYSTEMS, INC. amended Fifth Amendment with Synerx Pharma, LLC and Mylan Teoranta (effective 2024-04-22).

“On April 22, 2024, Delcath Systems, Inc. (“Delcath”) entered into a Fifth Amendment, effective May 1, 2024 (the “Amendment”), to the License, Supply and Contract Manufacturing Agreement with Synerx Pharma, LLC and Mylan Teoranta, dated October 13, 2010 (as subsequently amended, the “Agreement”), for Delcath’s supply of melphalan hydrochloride (the “Product”).”

STAR EQUITY HOLDINGS, INC. entered into Loan and Security Agreement with Keybank National Association valued at up to $4,000,000 (effective 2024-04-24).

“On April 24, 2024, KBS Builders, Inc. (the “Borrower”), a wholly-owned subsidiary of the Star Equity Holdings, Inc. (the “Company”), entered into a Loan and Security Agreement (the “Keybank Loan Agreement”) with Keybank National Association (“Keybank”) providing the Borrower with a working capital line of credit of up to $4,000,000”

Blaize Holdings, Inc. amended Merger Agreement Amendment with BurTech, BurTech Merger Sub Inc., Blaize, Burkhan valued at Increased Base Purchase Price from $700 million to $767 million; revised definitions (effective 2024-04-22).

“On April 22, 2024, BurTech, BurTech Merger Sub Inc., Blaize and Burkhan entered into an Amendment to Agreement and Plan of Merger (the " Merger Agreement Amendment ")”

Blaize Holdings, Inc. entered into Sponsor Forfeiture Agreement with BurTech LP LLC valued at Sponsor agreed to forfeit 2,000,000 BurTech Shares (effective 2024-04-22).

“Backstop Subscription Agreement On April 22, 2024, BurTech LP LLC (the “ Sponsor ”) entered into a backstop subscription agreement (the “ Backstop Subscription Agreement ”) with BurTech and Blaize.”

Blaize Holdings, Inc. entered into Backstop Subscription Agreement with BurTech LP LLC valued at Sponsor shall purchase BurTech Shares if Trust Amount less than $30,000,000 (effective 2024-04-22).

“On April 22, 2024, BurTech LP LLC (the " Sponsor ") entered into a backstop subscription agreement (the " Backstop Subscription Agreement ") with BurTech and Blaize”

Blaize Holdings, Inc. entered into Ava Letter Agreement with Ava Investors SA valued at Concurrent issuance of pre-funded warrants (effective 2024-04-22).

“inancing ”) to Ava Investors SA, a société anonyme incorporated under the laws of Switzerland (“ Ava ”, together with its affiliates and their respective transferees,”

Blaize Holdings, Inc. entered into RT Letter Agreement with RT-AI I, LLC valued at Convertible note financing of up to $125.0 million; $70.0 million funded as of April 22, 2024 (effective 2024-04-22).

“on April 22, 2024, of which $70.0 million were funded to Blaize as of such date, BurTech consented to a letter agreement (the " RT Letter Agreement ") between Blaize and RT-AI I, LLC”

PHOENIX MOTOR INC. entered into Waiver with JAK Opportunities II LLC (effective 2024-04-05).

“As of April 5, 2024, Phoenix Motor Inc., a Delaware corporation (the “Company”), entered into a waiver letter (the “Waiver”) by and between the Company and JAK Opportunities II LLC (the “Investor”), pursuant to which the Investor waived its right to require the Company to sell $12 million of principal amount of the Company’s secured senior convertible promissory note to the Investor pursuant to the Securities Purchase Agreement, dated as of November 10, 2023, with the Investor.”

La Rosa Holdings Corp. amended Amendment with Yeimalis Acevedo-Rasmussen valued at $2,413.99 (effective 2024-04-26).

“On April 26, 2024, La Rosa Holdings Corp., a Nevada corporation (the “Company”), and Yeimalis Acevedo-Rasmussen (“Selling Stockholder”) entered into an amendment agreement (the “Amendment”) to correct an inadvertent error in the original stock purchase agreement, dated March 15, 2024 (the “Purchase Agreement”)”

Berenson Acquisition Corp. I entered into Cable Car Guaranty with certain direct and indirect subsidiaries of Custom Health (effective 2024-04-22).

“Certain direct and indirect subsidiaries of Custom Health also provided a guaranty (the “Cable Car Guaranty”), whereby each of them unconditionally guaranteed, as primary obligor and not merely as surety, the prompt and complete payment and performance when due, whether by demand, acceleration or otherwise, of the obligations of Custom Health under the Cable Car Promissory Note in the currency in which and as such obligations are to be paid or performed”

Berenson Acquisition Corp. I entered into Cable Car Promissory Note with Funicular Funds, LP valued at $3,500,000 (effective 2024-04-22).

“Pursuant to the Cable Car NPA, Cable Car purchased $3,500,000 of convertible notes (“First Tranche”), as was evidenced by a promissory note (the “Cable Car Promissory Note”) dated April 22, 2024, by and between Custom Health and Cable Car as the Lead Buyer and Collateral Agent”

Berenson Acquisition Corp. I entered into Senior Secured Note Purchase Agreement with Funicular Funds, LP and other buyers valued at $15,000,000 (effective 2024-04-22).

“On April 22, 2024, BACA, Custom Health, and certain direct and indirect subsidiaries of Custom Health, entered into a Senior Secured Note Purchase Agreement (“Cable Car NPA”) with Funicular Funds, LP (“Cable Car”) and other buyers who purchase Notes from time to time under the Cable Car NPA, pursuant to which Custom Health authorized the issuance of a new series of Senior Secured Convertible Notes of Custom Health, up to, in the aggregate, an original principal amount of $15,000,000 (collectively, the “Notes” and each a “Note”)”

Roadzen Inc. entered into Securities Purchase Agreement with Supurna VedBrat and Krishnan-Shah Family Partners, LP valued at up to $2 million (effective 2024-03-28).

“on March 28, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with Supurna VedBrat and Krishnan-Shah Family Partners, LP (together, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company, an aggregate of up to $2 million in principal amount of senior secured notes (the “Notes”).”

SEP Acquisition Corp. amended Amendment Number Two (the “Amendment”) to the Agreement and Plan of Merger with SANUWAVE Health, Inc. (effective 2024-04-25).

“On April 25, 2024, SEP Acquisition Corp., a Delaware corporation (the “Company”), and SANUWAVE Health, Inc., a Nevada corporation (“SANUWAVE”), entered into that certain Amendment Number Two (the “Amendment”) to the Agreement and Plan of Merger, dated as of August 23, 2023, by and among the Company, SANUWAVE and SEP Acquisition Holdings Inc., a Nevada corporation and a wholly owned subsidiary of the Company (as amended, the “Merger Agreement”).”

TortoiseEcofin Acquisition Corp. III entered into Subscription Agreement with TortoiseEcofin Sponsor III LLC, One Energy Enterprises Inc., and a third-party investor valued at Capital contribution of $400,000, 200,000 Pubco shares, cash payment of $200,000, potential 800,000 (effective 2024-04-25).

“Additionally, also in connection with the April Extension Meeting and the Month-to-Month Extension Payments described above, including the Sponsor’s obligations in respect thereof, on April 25, 2024, the Company, the Sponsor, One Energy and a third-party investor (the “ Investor ”) entered into a subscription agreement (the “ Subscription Agreement ”) in the form attached as Exhibit 10.2 hereto, which is incorporated herein by reference.”

TortoiseEcofin Acquisition Corp. III entered into Loan and Transfer Agreements with TortoiseEcofin Sponsor III LLC, One Energy Enterprises Inc., and four investors valued at Loan of $350,000, additional cash payment of $175,000, 175,000 Class B ordinary shares (effective 2024-04-17).

“On April 17, 2024, the Company, the Sponsor, One Energy Enterprises Inc. (“ One Energy ”) and four investors (collectively, the “ Lenders ”) entered into Loan and Transfer Agreements (the “ Loan and Transfer Agreements ”) pursuant to which the Lenders, collectively, agreed to loan an aggregate of $350,000 to the Sponsor (the “ Loan ”), which the Sponsor intends to loan to the Company (the “ SPAC Loan ”), in each case in connection with the April Extension and the Month-to-Month Extension Payments.”

Hanover Bancorp, Inc. /MD entered into Exchange Agreement with Castle Creek Capital Partners VIII, L.P. (effective 2024-04-25).

“On April 25, 2024, Hanover Bancorp, Inc. (the “Company”) entered into an Exchange Agreement (the “Exchange Agreement”) with Castle Creek Capital Partners VIII, L.P. (“Castle Creek”).”

Clene Inc. entered into Amended and Restated License Agreement with 4Life Research, LLC valued at exclusive, royalty bearing license; royalty rate 3% of incremental sales; term through 2033 (effective 2024-04-25).

“On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.”

Clene Inc. entered into Amended and Restated Exclusive Supply Agreement with 4Life Research, LLC valued at cost plus 20% purchase price; Minimum Sales Commitments through 2033; royalty rate 3% of incremental (effective 2024-04-25).

“On April 25, 2024, Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine, Inc. (together with Clene Inc. and its other subsidiaries, the “Company”), entered into an amended and restated exclusive supply agreement (the “Supply Agreement”) and an amended and restated license agreement (the “License Agreement” and, collectively with the Supply Agreement, the “Amended 4Life Agreements”) with 4Life Research, LLC (“4Life”), an international supplier of health supplements, stockholder, and related party.”

NEXTNRG, INC. entered into Note with NextNRG Holding Corp. (formerly Next Charging, LLC) ("Next") valued at $165,000 (effective 2024-04-22).

“On April 22, 2024, EzFill Holdings, Inc. (the “Company”) and NextNRG Holding Corp. (formerly Next Charging, LLC) (“Next”) entered into a promissory note (the “Note”) for the sum of $165,000 (the “Loan”) to be used for the Company’s working capital needs.”

Renalytix plc entered into Placing Agreement with Stifel Nicolaus Europe Limited valued at up to an aggregate of 46,801,872 ordinary shares (effective 2024-03-12).

“on March 12, 2024, Renalytix plc (the “ Company ”) entered into a Placing Agreement (the “ Placing Agreement ”) with Stifel Nicolaus Europe Limited”

Vertex, Inc. entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $345 million aggregate principal amount of notes (effective 2024-04-26).

“The notes were issued pursuant to, and are and will be governed by, an indenture, dated as of the Closing Date (the “Indenture”), between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).”

Vertex, Inc. entered into Purchase Agreement with Morgan Stanley & Co. LLC as representative of the several initial purchasers valued at $300 million aggregate principal amount (effective 2024-04-23).

“On April 23, 2024, Vertex, Inc. (the “Company”) agreed to sell to the several initial purchasers (the “Initial Purchasers”) for whom Morgan Stanley & Co. LLC acted as representative (the “Representative”), and the Initial Purchasers agreed to purchase from the Company, $300 million aggregate principal amount of the Company’s 0.750% Convertible Senior Notes due 2029 (the “base notes”), pursuant to a purchase agreement (the “Purchase Agreement”) between the Company and the Representative.”

Concentrix Corp amended Third Amendment to the Receivables Financing Agreement with Concentrix Receivables, Inc., PNC Bank, National Association valued at up to $600 million (effective 2024-04-25).

“On April 25, 2024, Concentrix Corporation (the “Company”), as servicer, entered into an amendment (the “Amendment”) to its accounts receivable securitization facility (as amended, the “Securitization Facility”) by and among Concentrix Receivables, Inc., a subsidiary of the Company, as borrower, PNC Bank, National Association, as administrative agent, and the group agents and the lenders party thereto.”

Interactive Strength, Inc. entered into Loan Restoration Agreement with Vertical Investors, LLC (effective 2024-04-24).

“(the "Company") entered into a Credit Agreement (the “Credit Agreement”) with Vertical Investors, LLC (the “Lender”), pursuant to which the Company received a term loan from the Lender in the original principal amount of $7,968,977.74 (the “Loan”).”

Interactive Strength, Inc. amended Loan Modification Agreement with Vertical Investors, LLC (effective 2024-04-24).

“On April 24, 2024 (the “Effective Date”), the Company entered into a Loan Modification Agreement with the Lender (the “Modification Agreement”).”

Onconetix, Inc. amended Altos Amendment with Altos Ventures (effective 2024-04-24).

“On April 24, 2024, the Debenture was amended to extend the maturity date to the earlier of (i) the closing under the Subscription Agreement and (ii) October 31, 2024 (the "Altos Amendment").”

Onconetix, Inc. entered into Forbearance Agreement with Veru Inc. (effective 2024-04-24).

“(the “Company”) entered into an asset purchase agreement with Veru Inc., a Wisconsin corporation (“Veru”) (the “Veru APA”). Pursuant to the terms of the Veru APA, the Company agreed to provide Veru”

Inmune Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at 6% cash fee of gross proceeds (effective 2024-04-24).

“Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 24, 2024, between the Company and Maxim Group LLC (the “Placement Agent”), the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.”

Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 986,000 shares of common stock and warrants at $9.84 per share, aggregate gross proceeds $9,702,240 (effective 2024-04-24).

“On April 24, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser set forth on the signature page thereto (the “Purchasers) for the purchase and sale of an aggregate of 986,000 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 986,000 shares of its common stock (“Warrants”) in a registered direct offering.”

Datavault AI Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at aggregate fee equal to 8.0% of the gross proceeds raised in the Offerings (effective 2024-04-26).

“on April 26, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (the “Placement Agent”)”

Datavault AI Inc. entered into Purchase Agreement with certain purchasers valued at aggregate gross proceeds of approximately $2,400,000 (effective 2024-04-26).

“On April 26, 2024, WiSA Technologies, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain purchasers”

Morphic Holding, Inc. terminated Open Market Sale Agreement SM with Jefferies LLC (effective 2024-04-25).

“As previously disclosed, in July 2020, the Company entered into an Open Market Sale Agreement SM (as amended by Amendment No. 1 to the Open Market Sale Agreement SM , the "Prior Agreement") with Jefferies LLC ("Jefferies") under which the Company could offer and sell, from time to time at its sole discretion, shares of Common Stock having an aggregate offering amount of up to $150,000,000 through Jefferies as sales agent. In connection with the Company's entry into the TD Cowen Sales Agreement, on April 25, 2024, the Company terminated the Prior Agreement.”

Morphic Holding, Inc. entered into TD Cowen Sales Agreement with TD Securities (USA) LLC valued at $350,000,000 (effective 2024-04-26).

“On April 26, 2024, Morphic Holding, Inc., a Delaware corporation (the "Company" or "Morphic"), entered into a Sales Agreement (the "TD Cowen Sales Agreement") with TD Securities (USA) LLC ("TD Cowen"), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share ("Common Stock"), having an aggregate offering price of up to $350,000,000”

Lightstone Value Plus REIT IV, Inc. entered into Moxy Junior Loan with G4 18263, LLC valued at $9.0 million (effective 2024-04-19).

“and a $9.0 million junior mortgage loan facility (the “Moxy Junior Loan” and together with the Moxy Senior Loan, the “Moxy Mortgage Loans”) with G4”

Lightstone Value Plus REIT IV, Inc. entered into Moxy Senior Loan with Western Alliance Bank and G4 18263, LLC valued at $86.0 million (effective 2024-04-19).

“On April 19, 2024, a 75% majority owned subsidiary (the “Williamsburg Moxy Joint Venture”) of Lightstone Value Plus REIT IV, Inc. entered into an $86.0 million senior mortgage loan facility (the “Moxy Senior Loan”) with Western Alliance Bank and G4 18263, LLC (“G4”), both unrelated third parties”

Qorvo, Inc. entered into Credit Agreement with Bank of America, N.A., as administrative agent, swing line lender and letter of credit issuer, and a syndicate of lenders valued at $325.0 million (effective 2024-04-23).

“On April 23, 2024, Qorvo, Inc. (the “Company”) entered into a five-year unsecured senior credit facility pursuant to a credit agreement with Bank of America, N.A., as administrative agent (in such capacity, the “Administrative Agent”), swing line lender and letter of credit issuer, and a syndicate of lenders (the “Credit Agreement”).”

Lipocine Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at terminated effective immediately upon notice; waiver of notice period (effective 2024-04-24).

“On April 24, 2024, the Company provided notice to Cantor Fitzgerald & Co. (“Cantor”) of its election to terminate the Controlled Equity Offering SM Sales Agreement between them dated March 6, 2017 (the “Sales Agreement”).”

Lipocine Inc. entered into ATM Agreement with A.G.P./Alliance Global Partners valued at up to $10,616,169 of Shares; 3.0% of aggregate gross proceeds per sale (effective 2024-04-26).

“On April 26, 2024, Lipocine Inc. (the “Company”), entered into a sales agreement (the “ATM Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell shares of common stock, par value $0.0001 per share (the “Shares”), from time to time, in an at-the-market public offering.”

U.S. SILICA HOLDINGS, INC. entered into Merger Agreement with Star Holding LLC and Star Merger Co. valued at $15.50 in cash (effective 2024-04-26).

“On April 26, 2024, U.S. Silica Holdings, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Star Holding LLC, a Delaware limited liability company (“ Parent ”), and Star Merger Co., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”).”

Sixth Street Specialty Lending, Inc. amended fifteenth amendment to the Company’s second amended and restated senior secured revolving credit facility valued at from $1.685 billion as of March 31, 2024 to $1.70 billion (effective 2024-04-24).

“On April 24, 2024, Sixth Street Specialty Lending, Inc. (the “Company”) entered into a fifteenth amendment to the Company’s second amended and restated senior secured revolving credit facility, dated February 27, 2014 (as amended, the “Revolving Credit Facility”), which, among other changes, (a) increases the aggregate commitments under the Revolving Credit Facility from $ 1.685 billion as of March 31, 2024 to $1.70 billion and (b) extends the termination of the revolving period on $ 1.505 billion of commitments to April 24, 2028 and the stated maturity date to April 24, 2029.”